Computational Evaluation of nAChR and Transferrin Receptor Pathways for Human Rabies Treatment

Overview

Human rabies is a zoonotic viral disease transmitted from animals to humans, and is virtually 100% fatal post-symptom onset, primarily due to the virus's ability to evade the immune system and permeate the blood-brain barrier. This study explores a bispecific-nanobody targeting transferrin receptors and caffeine-operated synthetic module complex targeting nicotinic acetylcholine receptors as a potential rabies treatment, once fatal. My literature review examined rabies pathogenesis and viral entry mechanisms. In-silico modelling and protein docking were used to evaluate engineered nanobody sequences for binding to the rabies virus glycoprotein and host receptors. My docking studies revealed favourable binding conformations, indicating dual-targeting as an enhanced therapeutic delivery to the central nervous system. Safety and immunogenicity analyses showed non-toxic profiles and low allergenicity. MHC binding predictions suggested minimal adverse immune response. My research outlines a novel strategy to address challenges in rabies treatment, potentially leading to next-generation antiviral therapies for symptomatic patients.

Awards (2)

• Bronze Medal
• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.